NUWENUWEHealthcare · Medical Devices

NUWE Stock Forecast: Nuwellis, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$3.41
−10.50% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 18 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$2.1M
Ticker Nerd rank
18/ 100
Median analyst target
—
Analysts covering
1
Revenue$2.0M+14.1% y/y
Operating income−$3.2M
Net income−$4.8M
Free cash flow−$3.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−30.4%
1M
+520.0%
YTD
−94.4%
1Y
−95.3%
From 52W high
−97.7%
From 52W low
+965.6%
$0
$147
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Nuwellis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
18/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
53
Growth
48
Quality
40
Issuance
33
Momentum
24
Revisions
20
Volatility
7
Value
0

Accruals (53): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (0): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NUWE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NUWE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150Jan 26Apr 26Jul 26Oct 26NUWE

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0
Buy
1
Hold
0
Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Aug 2024Roth MKMReiteratesBuy$17
29 July 2024Roth MKMInitiatesBuy—
8 Nov 2023Ladenburg ThalmannDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NUWE.

Market Radar

This page is one stock. Monday covers all of them.

NUWE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

NUWE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Nuwellis, Inc. returned −95.3% against +6.9% for the S&P 500, dividends included.

NUWE vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200Jan 26Apr 26Jul 26Oct 26NUWES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NUWE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 99% of US stocks

Price / sales
0.2×

Cheaper than 90% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
14.1%

Higher than 62% of US stocks

Earnings growth (YoY)
—
Gross margin
76.1%

Higher than 88% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−87.8%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Nuwellis, Inc. has a market value of $2.1M.

  • Revenue in the twelve months to 30 June 2026: $9.0M. The latest quarter grew 14.1% year on year.

  • Net income over the same four quarters: −$11.3M, a −125.6% net margin.

  • Diluted earnings per share, trailing twelve months: −$132.69.

  • Free cash flow in the twelve months to 30 June 2026: −$12.7M.

  • Shares outstanding: 364,295.

  • Trailing P/E: 0.0×.

  • Nuwellis, Inc. employs 38 people — $237K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

NUWE and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
NUWENuwellis, Inc.$2.1M18
PFSAProfusa, Inc.$1.8M19
VVOSVivos Therapeutics, Inc.$1.8M43
BJDXBluejay Diagnostics, Inc.$1.9M17
AMIXAutonomix Medical, Inc.$1.7M31
ADGMAdagio Medical Holdings, Inc.$1.7M24
NXLNexalin Technology, Inc.$1.7M24

Take a look at NUWE’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Nuwellis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about NUWE

Is NUWE stock a buy right now?

Of the 1 analyst covering Nuwellis, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nuwellis, Inc. 18 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NUWE?

As at 21 Nov 2026, Nuwellis, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (53 of 100).

What is the NUWE stock forecast for 2030?

No analyst covering Nuwellis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NUWE are extrapolating price history, which says nothing about the business.

How has NUWE stock performed over the past year?

Nuwellis, Inc. returned -95.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nuwellis, Inc. do?

Nuwellis, Inc. is a medical technology company focused on fluid management for patients with cardiorenal and cardiovascular conditions. The company develops and commercializes ultrafiltration therapy systems, including the Aquadex SmartFlow and Aquadex FlexFlow platforms, which are designed to remove excess fluid when conventional medical management, such as diuretics, is not sufficient.

Company

About Nuwellis, Inc.

Nuwellis, Inc. is a medical technology company focused on fluid management for patients with cardiorenal and cardiovascular conditions. The company develops and commercializes ultrafiltration therapy systems, including the Aquadex SmartFlow and Aquadex FlexFlow platforms, which are designed to remove excess fluid when conventional medical management, such as diuretics, is not sufficient. Its devices are used in hospital settings for adult and pediatric patients, supporting clinicians in acute and critical care environments. Nuwellis serves the healthcare market through products intended to address fluid overload, a condition associated with heart failure and related complications. Headquartered in Eden Prairie, Minnesota, Nuwellis concentrates on specialized medical devices that help providers manage complex fluid-balance needs across a range of clinical settings.

CEO Mr. Michael Kendrick McCormick · 38 employees · United States · https://www.nuwellis.com